|Other Names||Phosphoinositide 3-kinase adapter protein 1, B-cell adapter for phosphoinositide 3-kinase, B-cell phosphoinositide 3-kinase adapter protein 1, PIK3AP1, BCAP|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Signaling adapter that contributes to B-cell development by linking B-cell receptor (BCR) signaling to the phosphoinositide 3-kinase (PI3K)-Akt signaling pathway. Has a complementary role to the BCR coreceptor CD19, coupling BCR and PI3K activation by providing a docking site for the PI3K subunit PIK3R1. Alternatively, links Toll-like receptor (TLR) signaling to PI3K activation, a process preventing excessive inflammatory cytokine production. Also involved in the activation of PI3K in natural killer cells. May be involved in the survival of mature B-cells via activation of REL.|
|Cellular Location||Cytoplasm. Cell membrane; Peripheral membrane protein|
|Tissue Location||Expressed in natural killer (NK) cells.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
PIK3AP1 is involved in the activation of phosphoinositide 3-kinase (PI3K) in B-cells and in natural killer (NK) cells. Couples B-cell antigen receptor (BCR) to PI3K activation by providing a docking site for the PI3K subunit PIK3R1, which contributes to B-cell development. Seems to have a complementary role with CD19 in PI3K activation (By similarity). May be involved in the survival of mature B cells via activation of REL (By similarity).
Koutros, S., et al. Cancer Res. 70(6):2389-2396(2010)Rikova, K., et al. Cell 131(6):1190-1203(2007)Grupe, A., et al. Am. J. Hum. Genet. 78(1):78-88(2006)Maruoka, M., et al. FEBS Lett. 579(14):2986-2990(2005)Okada, T., et al. Immunity 13(6):817-827(2000)
If you have any additional inquiries please email technical services at email@example.com.